<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37545" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Levofloxacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Podder</surname>
            <given-names>Vivek</given-names>
          </name>
          <aff>Tairunnessa Memorial Medical College and Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sadiq</surname>
            <given-names>Nazia M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vivek Podder declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazia Sadiq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37545.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Levofloxacin is FDA-approved for the treatment of nosocomial pneumonia, community-acquired pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbation of chronic bronchitis, acute bacterial prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis, and treatment of plaque due to <italic toggle="yes">Yersinia pestis</italic>, and to reduce the incidence of disease progression of inhalational anthrax.&#x000a0;The drug is in the fluoroquinolone class of medications, and adverse effects include pseudomembranous colitis, hepatotoxicity, and QT prolongation, necessitating patient education on discontinuation if such symptoms arise. This activity reviews monitoring strategies, FDA-issued box warnings, clinical toxicology, and relevant interactions pertinent to healthcare team members in treating patients with bacterial infections.</p>
        <p>Given this fluoroquinolone's relevance in primary and specialized care, contextualizing the indications of levofloxacin leads to improved clinical practice.&#x000a0;Participating clinicians are equipped&#x000a0;with the knowledge to seamlessly integrate levofloxacin into the patient-centric framework of clinical practice, ensuring the optimal treatment of bacterial infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of levofloxacin compared to antibiotics of its class.</p></list-item><list-item><p>Differentiate between the FDA-approved and off-label&#x000a0;indications of levofloxacin, selecting alternatives when needed.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse effects, contraindications, and risk factors before prescribing&#x000a0;levofloxacin.</p></list-item><list-item><p>Implement effective communication among interprofessional team members to improve treatment efficacy for patients who might benefit from levofloxacin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37545&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37545">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37545.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibiotic used to treat bacterial infections. Levofloxacin is&#x000a0;a safe and effective medicine on the World Health Organization's&#x000a0;essential medicines list. The antibiotic<bold>&#x000a0;</bold>was patented in 1987 and subsequently received FDA approval in 1996 for medical use in the United States.<xref ref-type="bibr" rid="article-37545.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial pneumonia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Community-acquired pneumonia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin and skin structure infections (SSTI) complicated and uncomplicated&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic bacterial prostatitis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute bacterial exacerbation of chronic bronchitis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute bacterial sinusitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inhalational anthrax, post-exposure in adult and pediatric patients</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Plague in adult and pediatric patients&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Urinary tract infections (UTI)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute pyelonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial conjunctivitis (ophthalmic formulation)<xref ref-type="bibr" rid="article-37545.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic foot infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Osteomyelitis<xref ref-type="bibr" rid="article-37545.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Due to an increased risk of severe&#x000a0;adverse effects (eg, tendinitis and tendon rupture, peripheral neuropathy, and CNS effects), levofloxacin&#x000a0;is used in patients with acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and uncomplicated urinary tract infections&#x000a0;that do not have alternative treatment options.<xref ref-type="bibr" rid="article-37545.r4">[4]</xref></p>
        <p>To decrease the development of drug-resistant bacteria, the FDA has recommended&#x000a0;using&#x000a0;levofloxacin only<bold>&#x000a0;</bold>for strongly suspected bacterial infections. Also, levofloxacin<bold>&#x000a0;</bold>should not be used empirically in patients at risk of multidrug-resistant&#x000a0;<italic toggle="yes">Escherichia coli</italic>.<xref ref-type="bibr" rid="article-37545.r5">[5]</xref>&#x000a0;According to Infectious Diseases Society of America (IDSA) 2022 guidelines, levofloxacin is suggested for infections caused by ESBL-E (extended-spectrum &#x003b2;-lactamase-producing&#x000a0;<italic toggle="yes">enterobacterales</italic><italic toggle="yes">)</italic>, AmpC-E (AmpC &#x003b2;-lactamase-producing&#x000a0;<italic toggle="yes">enterobacterales</italic>), or <italic toggle="yes">Stenotrophomonas maltophilia&#x000a0;</italic>(mild infection).<xref ref-type="bibr" rid="article-37545.r6">[6]</xref></p>
      </sec>
      <sec id="article-37545.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Levofloxacin is&#x000a0;a bactericidal antibiotic of the fluoroquinolone drug class that directly inhibits bacterial DNA synthesis.&#x000a0;Levofloxacin promotes the breakage of DNA strands by inhibiting DNA-gyrase in susceptible organisms, which inhibits the relaxation of supercoiled DNA.&#x000a0;Of the fluoroquinolone class,&#x000a0;levofloxacin has the most enhanced activity against gram-positive penicillin-sensitive and resistant organisms, notably&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic><italic toggle="yes">&#x000a0;</italic>and reduced&#x000a0;action against gram-negative bacilli, notably&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa,</italic>&#x000a0;compared to ciprofloxacin.&#x000a0;Levofloxacin&#x000a0;has effectiveness against other common respiratory organisms, notably&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>,&#x000a0;<italic toggle="yes">Moraxella catarrhalis</italic>,<italic toggle="yes">&#x000a0;</italic><italic toggle="yes">Legionella spp</italic>,&#x000a0;<italic toggle="yes">Mycoplasma spp</italic>,<italic toggle="yes">&#x000a0;</italic>and&#x000a0;<italic toggle="yes">Chlamydia</italic>&#x000a0;<italic toggle="yes">pneumoniae</italic>.<xref ref-type="bibr" rid="article-37545.r5">[5]</xref>&#x000a0;Levofloxacin&#x000a0;also<bold>&#x000a0;</bold>has a higher in-vitro activity against <italic toggle="yes">Mycobacterium&#x000a0;tuberculosis</italic>&#x000a0;and is preferred over the other fluoroquinolones as second-line&#x000a0;antitubercular therapy.<xref ref-type="bibr" rid="article-37545.r7">[7]</xref>&#x000a0;A&#x000a0;growing concern about drug resistance to fluoroquinolones exists worldwide, which can occur&#x000a0;through chromosome-encoded or plasmid-mediated mechanisms.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Levofloxacin is&#x000a0;rapidly absorbed and widely distributed in the body. The bioavailability of levofloxacin&#x000a0;is 99%; therefore,&#x000a0;levofloxacin's intravenous (IV) and oral&#x000a0;preparations are used interchangeably. The time to peak plasma concentration (Tmax) is approximately 1.5 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;The volume of distribution of levofloxacin generally varies from 74 to 112&#x000a0;L (single and multiple 500 or 750 mg doses), demonstrating&#x000a0;extensive&#x000a0;distribution in body tissues. Outcomes of the study&#x000a0;suggest&#x000a0;that&#x000a0;levofloxacin is widely distributed in the skin, muscles, liver, kidney, and spleen.&#x000a0;Drug concentrations in tissues and fluids are typically&#x000a0;higher&#x000a0;than in plasma. Levofloxacin has plasma protein binding of&#x000a0;&#x000a0;24% to 38%&#x000a0;and&#x000a0;binds primarily to albumin.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Levofloxacin undergoes little hepatic metabolism in humans and is eliminated unchanged in the urine.<xref ref-type="bibr" rid="article-37545.r8">[8]</xref></p>
        <p><bold>Excretion:</bold> Levofloxacin clearance is primarily via the renal route (87%).&#x000a0;The mean plasma elimination half-life of levofloxacin&#x000a0;is approximately 6 to 8 hours following single or multiple doses of levofloxacin.<xref ref-type="bibr" rid="article-37545.r9">[9]</xref></p>
      </sec>
      <sec id="article-37545.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Levofloxacin is available in oral tablets, oral solutions, and intravenous (IV) formulations. Levofloxacin is unavailable for administration through intramuscular (IM), intrathecal, or subcutaneous (SQ) routes. The marketed oral dosage strengths for levofloxacin are 250, 500, and 750 mg. Oral dosing with tablets can be without regard to meals. However, the oral solution should be taken 1 hour before or 2 hours after meals. Patients should avoid using antacids, or levofloxacin should be administered&#x000a0;2 hours before or&#x000a0;2 hours after taking antacids containing magnesium or aluminum. Adequate hydration is essential to prevent crystalluria.&#x000a0;</p>
        <p>Levofloxacin injection should be administered for adult and pediatric patients by slow&#x000a0;IV infusion over 60 minutes (250 to 500 mg) and over 90 minutes (for 750 mg). Due to an increased risk of hypotension, bolus or rapid&#x000a0;IV administration should be avoided. In addition, the infusion should not use a solution containing multivalent cations. The ophthalmic levofloxacin solution is a safe and effective antibiotic used for&#x000a0;7 days to treat bacterial conjunctivitis.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended oral dose regimen is 750 mg daily to treat nosocomial pneumonia, complicated skin and skin structure infections (7 to 14 days), community-acquired pneumonia, acute bacterial sinusitis, complicated urinary tract infection (UTI), or acute pyelonephritis (5 days).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The daily dosing of 500 mg daily is recommended to treat nosocomial pneumonia (7 to 14 days), acute bacterial sinusitis (5 to 14 days), acute bacterial exacerbation of chronic bronchitis (7 days), uncomplicated skin and skin structure infections (7 to 10 days), chronic bacterial prostatitis (28 days), and post-exposure inhalational anthrax (60 days).<xref ref-type="bibr" rid="article-37545.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The daily dosing of 250 mg is recommended for patients with complicated urinary tract infections, acute pyelonephritis (10 days), or uncomplicated urinary tract infections (3 days).<xref ref-type="bibr" rid="article-37545.r1">[1]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The daily dosing of 750 mg IV or orally daily (5-day regimen) is recommended for complicated UTIs or acute pyelonephritis.<xref ref-type="bibr" rid="article-37545.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No dose adjustment is provided in the manufacturer's labeling. As levofloxacin is eliminated primarily by the kidney and undergoes minimal hepatic metabolism, dose adjustment may not be required. In addition, levofloxacin is used in patients with cirrhosis to prevent spontaneous bacterial peritonitis (SBP). The preferred drug for SBP prophylaxis is 3rd generation cephalosporin. Levofloxacin can be used in patients allergic to cephalosporins.<xref ref-type="bibr" rid="article-37545.r11">[11]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>A 50% reduction in the total daily dosage is recommended in patients with renal impairment (glomerular filtration rate between 10 and 50 mL/min) and extended to every 48 hours if the glomerular filtration rate falls less than 10 mL/min).<xref ref-type="bibr" rid="article-37545.r1">[1]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Guidelines for acute and recurrent urinary tract infections in pregnant women recommend using agents other than levofloxacin, such as amoxicillin/clavulanic acid and cefuroxime. According to joint guidelines published by the American Thoracic Society, CDC, European Respiratory Society, and IDSA, in patients with multi-drug resistant tuberculosis, levofloxacin can be considered in pregnancy if the benefits of treatment to the mother outweigh the harms.<xref ref-type="bibr" rid="article-37545.r12">[12]</xref>&#x000a0;However, the risk-benefit analysis should always be considered, and levofloxacin should be prescribed&#x000a0;if essential. Levofloxacin should generally be avoided during pregnancy.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Levofloxacin has not been used in infants because of consideration of adverse consequences on the infants' developing joints. Clinical data indicate that breast milk has a low concentration of levofloxacin, which is unlikely to cause damaging effects in breastfed babies. Using levofloxacin with breastfeeding mothers is acceptable with monitoring the infant for possible GI adverse effects (diarrhea or candidiasis). Additionally, pregnant women should be counseled not to breastfeed during treatment with levofloxacin and for&#x000a0;2 days after the last dose of levofloxacin.<xref ref-type="bibr" rid="article-37545.r13">[13]</xref></p>
        <p><bold>Pediatric patients</bold>:&#x000a0;The&#x000a0;AAP states that levofloxacin should be reserved only for managing infections with no effective alternative&#x000a0;due to the risk of tendinopathy and musculoskeletal toxicity.<xref ref-type="bibr" rid="article-37545.r14">[14]</xref>&#x000a0;The safety of extended levofloxacin tablet therapy in pediatric patients beyond 14 days has not been extensively studied. Prolonged use should only be considered when the potential benefits outweigh the associated risks. Initiate drug administration promptly following suspected or confirmed exposure to aerosolized <italic toggle="yes">Bacillus anthracis</italic> or <italic toggle="yes">Yersinia pestis</italic>.<xref ref-type="bibr" rid="article-37545.r15">[15]</xref></p>
        <p>Pediatric dosage (&#x02265; 6 Months of age)</p>
        <p>Inhalational Anthrax (Post-exposure)</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric patients &#x0003e;50 kg: Administer 500 mg every 24 hours as soon as possible after exposure.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric patients &#x0003c;50 kg and &#x02265;&#x000a0;6 months of age: Administer 8 mg/kg (not exceeding 250 mg per dose) every 12 hours for 60 days.</p>
          </list-item>
        </list>
        <p>Plague</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric patients &#x0003e;50 kg: Administer 500 mg every 24 hours for 10 to 14 days.</p>
          </list-item>
          <list-item>
            <p>Pediatric patients &#x0003c;50 kg and &#x02265;&#x000a0;6 months of age: Administer 8 mg/kg (not exceeding 250 mg per dose) every 12 hours for 10 to 14 days.</p>
          </list-item>
        </list>
        <p><bold>Older&#x000a0;patients:&#x000a0;</bold>Older patients on corticosteroid therapy have an increased risk of severe tendon disorders, including rupture, months after fluoroquinolone treatment, requiring prompt discontinuation if symptoms occur. Caution is advised in older patients due to potential QT interval effects, especially when co-administering drugs causing QT prolongation or in those with torsade de pointes risk factors. Hepatotoxicity has been reported in older patients. Immediate discontinuation is crucial if signs of hepatitis appear.<xref ref-type="bibr" rid="article-37545.r16">[16]</xref></p>
      </sec>
      <sec id="article-37545.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary adverse effects of levofloxacin include nausea, photosensitivity, diarrhea, headache, tendinitis, tendon rupture, hyper-hypoglycemia, seizures, prolonged QT interval, and peripheral neuropathy. Clinicians should carefully prescribe levofloxacin to patients with a history of prolonged QT intervals.<xref ref-type="bibr" rid="article-37545.r17">[17]</xref>&#x000a0;Avoid or minimize&#x000a0;exposure to natural or artificial sunlight while taking levofloxacin to reduce the occurrence of phototoxicity. Research has determined prolonged levofloxacin is linked with a higher risk of fungal and bacterial superinfection (eg, pseudomembranous colitis).<xref ref-type="bibr" rid="article-37545.r18">[18]</xref></p>
        <p>Levofloxacin can cause hepatotoxicity. The pattern of enzyme elevation is hepatocellular, cholestatic, or mixed. The cases of jaundice and vanishing bile duct syndrome have been described. Hepatotoxicity can be associated with immunoallergic presentations such as fever, rash, and eosinophilia. The latency to onset is usually short (1 to 3 weeks), and the onset is abrupt with enzyme elevation, jaundice, and sometimes hepatic failure. Hence, the likelihood score for hepatotoxicity is A (well-established cause of clinically apparent liver injury).<xref ref-type="bibr" rid="article-37545.r19">[19]</xref>&#x000a0;The FDA has warned that fluoroquinolones, including levofloxacin, elevate the risk of aortic aneurysm and aortic dissection. Avoid prescribing levofloxacin to older patients and patients with a history of Marfan or Ehlers-Danlos syndrome.<xref ref-type="bibr" rid="article-37545.r20">[20]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Concomitant administration of oral hypoglycemic agents such as glimepiride increases the risk of hypoglycemia. Careful monitoring of blood glucose is advised for patients taking concurrent antidiabetic medications due to the risk of glucose dysregulation.<xref ref-type="bibr" rid="article-37545.r21">[21]</xref>&#x000a0;Unlike ciprofloxacin, levofloxacin does not inhibit the drug-metabolizing enzyme CYP1A2; however, its weak inhibiting potential on the CYP2C9 enzyme, bleeding can occur with concurrent administration of warfarin.<xref ref-type="bibr" rid="article-37545.r22">[22]</xref>&#x000a0;A study indicates that simultaneous administration of levofloxacin with NSAIDs such as diclofenac can cause seizures.&#x000a0;A risk of QTc prolongation exists when levofloxacin and thioridazine are administered together.<xref ref-type="bibr" rid="article-37545.r23">[23]</xref>&#x000a0;Cations in aluminum hydroxide, magnesium oxide, ferrous sulfate, and calcium carbonate can chelate and reduce the absorption of levofloxacin. Consequently, these drugs should be administered at least&#x000a0;2 hours before or after levofloxacin.<xref ref-type="bibr" rid="article-37545.r24">[24]</xref>&#x000a0;A&#x000a0;study revealed that levofloxacin cross-reacts with immunoassays for&#x000a0;2 related opioids (buprenorphine and morphine). Urine concentrations of levofloxacin consistent with therapeutic use produced results above commonly used cutoffs for positivity, highlighting the necessity of confirmatory testing.<xref ref-type="bibr" rid="article-37545.r25">[25]</xref></p>
      </sec>
      <sec id="article-37545.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>The concurrent administration of levofloxacin with drugs that prolong the QT interval is contraindicated.<xref ref-type="bibr" rid="article-37545.r26">[26]</xref>&#x000a0;Levofloxacin should not be administered to patients with a confirmed hypersensitivity to the drug or its components, as anaphylaxis has been reported.<xref ref-type="bibr" rid="article-37545.r27">[27]</xref>&#x000a0;Fluoroquinolones, including levofloxacin, are contraindicated in pregnancy. Research has indicated that risk is highest during the first trimester; levofloxacin administration should generally be avoided during pregnancy and lactation unless a safer alternative is unavailable. More research is needed to establish the role of fluoroquinolone during pregnancy.<xref ref-type="bibr" rid="article-37545.r28">[28]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The FDA has issued a warning for using levofloxacin and other fluoroquinolones due to the increased risk of disabling and irreversible adverse effects, including tendinitis and tendon rupture, and central nervous system (CNS) effects (eg, seizures, increased intracranial pressure), peripheral neuropathy in all ages. Older patients &#x0003e; 60 years, those taking corticosteroids and with kidney, heart, or lung transplants, are at increased risk of severe tendon disorders.<xref ref-type="bibr" rid="article-37545.r29">[29]</xref>&#x000a0;Avoiding levofloxacin and other fluoroquinolone antibiotics is recommended in patients with myasthenia gravis due to an increased risk of exacerbating preexisting muscle weakness.<xref ref-type="bibr" rid="article-37545.r30">[30]</xref></p>
      </sec>
      <sec id="article-37545.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should monitor patients&#x000a0;prescribed levofloxacin for crystalluria, dysglycemia, altered mental status, CBC (especially white blood cell counts), and signs and symptoms of tendonitis and infection. During treatment,&#x000a0;periodic evaluation of&#x000a0;organ system functions is necessary. Monitoring for signs of bleeding is imperative due to the drug interaction between levofloxacin and warfarin. Levofloxacin affects the CYP2C9 enzyme, leading to elevated warfarin levels.<xref ref-type="bibr" rid="article-37545.r31">[31]</xref>&#x000a0;Unlike ciprofloxacin, monitoring patients concurrently&#x000a0;prescribed theophylline is unnecessary as levofloxacin does not inhibit the enzyme CYP1A2.<xref ref-type="bibr" rid="article-37545.r22">[22]</xref></p>
      </sec>
      <sec id="article-37545.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The elimination half-life of&#x000a0;levofloxacin&#x000a0;ranges from&#x000a0;27 to 35 hours&#x000a0;in adults with renal impairment, depending on severity, compared with&#x000a0;6 to&#x000a0;8 hours in healthy adults.&#x000a0;This prolonged half-life indicates that dosing adjustment is necessary for these patients.<bold>&#x000a0;</bold>Neurotoxicity, including non-convulsive status epilepticus, has been reported with levofloxacin.<xref ref-type="bibr" rid="article-37545.r32">[32]</xref> Levofloxacin has a low potential for acute toxicity; however, the stomach needs to be emptied during an acute overdose. The patient should be under observation with&#x000a0;adequate maintenance of hydration. Hemodialysis or peritoneal dialysis can not adequately remove&#x000a0;levofloxacin. The role of enhancing drug elimination with forced dilution is not clear. Activated oral charcoal administration is also a recommended approach with appropriate conditions.<xref ref-type="bibr" rid="article-37545.r13">[13]</xref></p>
      </sec>
      <sec id="article-37545.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Levofloxacin is a widely prescribed respiratory fluoroquinolone by many&#x000a0;clinicians for a broad spectrum of bacterial infections. Levofloxacin is well-known to increase the risk of&#x000a0;tendinitis and tendon rupture in all ages, especially in patients aged over 60, taking corticosteroids, and with a history of kidney, heart, or lung transplants. All&#x000a0;prescribers should stratify patients earlier for risk of complications and&#x000a0;sparingly use the drug for patients&#x000a0;with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections. Healthcare staff should counsel patients to maintain adequate hydration to prevent crystalluria and avoid antacids to enhance bioavailability. As levofloxacin excretion is primarily via the kidney,&#x000a0;clinicians should carefully adjust the dose in the presence of renal insufficiency to prevent levofloxacin accumulation.&#x000a0;Consultation with an infectious diseases specialist is&#x000a0;required&#x000a0;to treat resistant infections.</p>
        <p>Clinicians should monitor patients for changes in bowel frequency, fever, abdominal cramps, loss of appetite, nausea, vomiting, right upper quadrant tenderness, jaundice, dark-colored urine, or palpitations. Levofloxacin is&#x000a0;well-known to&#x000a0;cause&#x000a0;pseudomembranous colitis, hepatotoxicity, and QT prolongation; patients should receive education&#x000a0;to&#x000a0;discontinue treatment when the clinical features develop. If diarrhea develops, it is essential to manage fluid and electrolyte replacement in this patient population adequately. Due to the global concern regarding drug resistance of levofloxacin and other fluoroquinolones, limiting the duration of levofloxacin therapy and avoiding its empirical prescribing is important.</p>
        <p>A cross-sectional study examined changes in fluoroquinolone prescribing patterns following FDA warnings in 2013 and 2016. The research used Medicare data and&#x000a0;clinician information from 2011 to 2017, focusing on outpatient visits for specific conditions.&#x000a0;The study revealed a general decrease in fluoroquinolone prescriptions, with prescribing behavior influenced by physician and organizational attributes such as hospital affiliation and specialization. This research provides key insights for improving&#x000a0;fluoroquinolone&#x000a0;de-adoption strategies in response to FDA warnings, which can improve patient safety.<xref ref-type="bibr" rid="article-37545.r33">[33]</xref></p>
        <p>Clear communication between&#x000a0;clinicians (MD, DO, NP,&#x000a0; PA) and nurses is necessary to administer levofloxacin by slow infusion to avoid the risk of hypotension. Pharmacists need to verify dosing and treatment duration and check for drug-drug interactions. Nursing is on the front lines of observing adverse effects and promptly reporting these to the rest of the team. A concerted and collaborative interprofessional team effort between patients, clinicians, nurses, and pharmacists is necessary to achieve improved patient outcomes with reduced risk of&#x000a0;adverse drug reactions&#x000a0;and increased patient satisfaction related to levofloxacin therapy.</p>
      </sec>
      <sec id="article-37545.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37545&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37545">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37545/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37545">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37545.s11">
        <title>References</title>
        <ref id="article-37545.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bush</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Chaparro-Rojas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Okeh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Etienne</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.</article-title>
            <source>Infect Drug Resist</source>
            <year>2011</year>
            <volume>4</volume>
            <fpage>177</fpage>
            <page-range>177-89</page-range>
            <pub-id pub-id-type="pmid">22114510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sue</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hesse</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bulitta</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cato</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2023</year>
            <month>Nov</month>
            <day>17</day>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>1</fpage>
            <page-range>1-47</page-range>
            <pub-id pub-id-type="pmid">37963097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>OH</given-names>
              </name>
            </person-group>
            <article-title>Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e0211888</fpage>
            <pub-id pub-id-type="pmid">30735536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Witherspoon</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Knopf</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1055</fpage>
            <page-range>1055-1063</page-range>
            <pub-id pub-id-type="pmid">31500468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.</article-title>
            <source>Drugs</source>
            <year>2008</year>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>535</fpage>
            <page-range>535-65</page-range>
            <pub-id pub-id-type="pmid">18318569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America Guidance on the Treatment of AmpC &#x003b2;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>06</day>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2089</fpage>
            <page-range>2089-2114</page-range>
            <pub-id pub-id-type="pmid">34864936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yew</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.</article-title>
            <source>Chest</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>744</fpage>
            <page-range>744-51</page-range>
            <pub-id pub-id-type="pmid">10713001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.</article-title>
            <source>Eur J Drug Metab Pharmacokinet</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>395</fpage>
            <page-range>395-402</page-range>
            <pub-id pub-id-type="pmid">25753830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>The clinical pharmacokinetics of levofloxacin.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-19</page-range>
            <pub-id pub-id-type="pmid">9068926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Cen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750&#x000a0;mg/day) or conventional intravenous/oral levofloxacin (500&#x000a0;mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-507</page-range>
            <pub-id pub-id-type="pmid">28108978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dever</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1116</fpage>
            <page-range>1116-31</page-range>
            <pub-id pub-id-type="pmid">25819304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mase</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bothamley</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cegielski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fregonese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ahmad Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kheir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lardizabal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauzardo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mangan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mitnick</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Nilsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Parvez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wortham</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chorba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seaworth</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>200</volume>
            <issue>10</issue>
            <fpage>e93</fpage>
            <page-range>e93-e142</page-range>
            <pub-id pub-id-type="pmid">31729908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Levofloxacin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schutze</surname>
                <given-names>GE</given-names>
              </name>
              <collab>COMMITTEE ON INFECTIOUS DISEASES</collab>
            </person-group>
            <article-title>The Use of Systemic and Topical Fluoroquinolones.</article-title>
            <source>Pediatrics</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>138</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27940800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krug</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Meaney-Delman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
              <collab>AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council</collab>
            </person-group>
            <article-title>Pediatric anthrax clinical management.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>May</month>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>e1411</fpage>
            <page-range>e1411-36</page-range>
            <pub-id pub-id-type="pmid">24777226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided?</article-title>
            <source>CMAJ</source>
            <year>2012</year>
            <month>Oct</month>
            <day>02</day>
            <volume>184</volume>
            <issue>14</issue>
            <fpage>1555</fpage>
            <page-range>1555-6</page-range>
            <pub-id pub-id-type="pmid">22891207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone adverse effects and drug interactions.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10 Pt 2</issue>
            <fpage>253S</fpage>
            <page-range>253S-272S</page-range>
            <pub-id pub-id-type="pmid">11642691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ball</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>646</fpage>
            <page-range>646-61</page-range>
            <pub-id pub-id-type="pmid">24944413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Levofloxacin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2021</year>
            <month>Sep</month>
            <day>28</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>470</fpage>
            <pub-id pub-id-type="pmid">34583637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lodise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lomaestro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1498</fpage>
            <page-range>1498-505</page-range>
            <pub-id pub-id-type="pmid">17963459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.</article-title>
            <source>Acta Pharmacol Sin</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>1507</fpage>
            <page-range>1507-14</page-range>
            <pub-id pub-id-type="pmid">19026171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ismail</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harram</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Haq</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Khadim</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Muhammad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asif</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Potential drug-drug interactions in outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study.</article-title>
            <source>BMC Health Serv Res</source>
            <year>2018</year>
            <month>Oct</month>
            <day>10</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>762</fpage>
            <pub-id pub-id-type="pmid">30314487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitman</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>UTP</given-names>
              </name>
              <name>
                <surname>Wi</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Alsheikh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hiner</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Percival</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2019</year>
            <month>Jul</month>
            <day>31</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31370320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colby</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Rutherford</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.</article-title>
            <source>Clin Biochem</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>68</volume>
            <fpage>50</fpage>
            <page-range>50-54</page-range>
            <pub-id pub-id-type="pmid">30991036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briasoulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.</article-title>
            <source>Cardiology</source>
            <year>2011</year>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-10</page-range>
            <pub-id pub-id-type="pmid">22156660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>A case of levofloxacin-induced anaphylaxis with elevated serum tryptase levels.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-5</page-range>
            <pub-id pub-id-type="pmid">23450078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yefet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chazan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nachum</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis.</article-title>
            <source>BJOG</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>9</issue>
            <fpage>1069</fpage>
            <page-range>1069-1076</page-range>
            <pub-id pub-id-type="pmid">29319210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanne</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>FDA adds "black box" warning label to fluoroquinolone antibiotics.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Jul</month>
            <day>15</day>
            <volume>337</volume>
            <issue>7662</issue>
            <fpage>a816</fpage>
            <pub-id pub-id-type="pmid">18632714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sorbello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.</article-title>
            <source>Drug Saf</source>
            <year>2011</year>
            <month>Oct</month>
            <day>01</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>839</fpage>
            <page-range>839-47</page-range>
            <pub-id pub-id-type="pmid">21879778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Fugate</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Levofloxacin and warfarin interaction.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1554</fpage>
            <page-range>1554-7</page-range>
            <pub-id pub-id-type="pmid">12243605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Accardo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Primavera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Levofloxacin neurotoxicity and non-convulsive status epilepticus (NCSE): a case report.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>114</volume>
            <issue>10</issue>
            <fpage>1371</fpage>
            <page-range>1371-3</page-range>
            <pub-id pub-id-type="pmid">22551579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37545.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sankar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Karaca-Mandic</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Dec</month>
            <day>01</day>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>e2136662</fpage>
            <pub-id pub-id-type="pmid">34851398</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
